- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Endometrial transformation.
Displaying page 1 of 1.
EudraCT Number: 2015-000290-12 | Sponsor Protocol Number: 1412-BCN-087-AB | Start Date*: 2015-06-26 |
Sponsor Name:ClĂnica IVI Barcelona | ||
Full Title: Randomized Clinical Trial comparing the endometrial transformation with 25 mg/day of subcutaneous progesterone (Prolutex) versus 50 mg/day intramuscular progesterone (Prontogest) | ||
Medical condition: Infertility. Assisted Reproductive Techniques. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004684-58 | Sponsor Protocol Number: FE 200486 CS24 | Start Date*: 2007-01-08 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared... | |||||||||||||
Medical condition: Prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003773-42 | Sponsor Protocol Number: PM1183-B-005-14 | Start Date*: 2015-03-30 | |||||||||||
Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal | |||||||||||||
Full Title: A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors. | |||||||||||||
Medical condition: Selected Advanced Solid Tumors. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) SE (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003548-35 | Sponsor Protocol Number: MesaCAPP | Start Date*: 2017-03-10 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome | |||||||||||||
Medical condition: Colorectal Cancer Prevention in Lynch syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000059-38 | Sponsor Protocol Number: 21810 | Start Date*: 2021-11-17 | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women. | |||||||||||||
Medical condition: Vasomotor symptoms associated with menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004855-34 | Sponsor Protocol Number: 21652 | Start Date*: 2021-11-25 | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women | |||||||||||||
Medical condition: Vasomotor symptoms associated with menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) NO (Completed) PT (Completed) SK (Completed) PL (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004908-33 | Sponsor Protocol Number: 21651 | Start Date*: 2021-10-18 | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women | |||||||||||||
Medical condition: Vasomotor symptoms associated with menopause | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) HU (Completed) NL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
